The Microcap Newsletter
  • Deal Tables
  • News
  • Events
    • The Microcap Conference
    • The SPAC Conference
    • The Reg A Conference
    • The Venture Debt Conference
    • The DTC Healthcare Conference
    • The Healthcare Services
      Investment Conference
  • Free Sign Up
  • Register for The Microcap Conference
Free Sign Up
Attend The Microcap Conference
No Result
View All Result
The Microcap Newsletter
  • Deal Tables
  • News
  • Events
    • The Microcap Conference
    • The SPAC Conference
    • The Reg A Conference
    • The Venture Debt Conference
    • The DTC Healthcare Conference
    • The Healthcare Services
      Investment Conference
  • Free Sign Up
  • Register for The Microcap Conference
Free Sign Up
Attend The Microcap Conference
No Result
View All Result
The Microcap Newsletter
No Result
View All Result

Microcap IPO Flow Slows After Early Spring Surge

April 10, 2023

After a surge of microcap IPO activity at the end of March into the first week of April, the second week wanes with far fewer deals in the pipeline.

Renaissance Capital’s report on first-quarter trends said deal flow started at a decent pace, then lagged with hawkish signals from the Fed, recession fears, and banking industry turmoil.

The surge at the beginning of Q2 reinforces Renaissance Capital’s report, “there are plenty of candidates in the pipeline and shadow backlog that are still targeting 2023 debuts, should market conditions improve.”

Stop, Swap, and Go

Holdover U Power (UCAR) has an estimated IPO date of April 12 and seeks to raise $18 million at a $368 million market cap. Founded in 2013 and based in Shanghai, the company initially provided vehicle sourcing services and is now developing proprietary battery-swapping stations in China under the UOTTA brand. U Power booked $2 million in revenue for the year that ended June 30, 2022. The sole bookrunner is AMTD Global Markets.

Clinical Trials and Cancer

CytoMed Therapeutics (GDTC) has an estimated IPO date of April 14 and intends to raise $11 million at a $51 million cap. Founded in 2018 and based in Singapore, the pre-clinical biopharmaceutical company builds proprietary platform technologies for human cancer treatment. Three product candidates are in development, with CytoMed receiving a grant and finalizing a trial of its lead product at the National University Hospital Singapore and recruiting patients in the second half of 2023. Axiom Capital Management and the Benchmark Company are joint bookrunners.

Take a Deep Breath and Vape

Ispire Technology (ISPR) downsized and listed April 4 to raise $19 million at a $369 market cap and finished up 1%. Ispire researches, develops and distributes e-cigarettes and cannabis vaping products internationally, excluding Russia and China. Based in the United States, Ispire was founded in 2022 to acquire specific businesses of the Chinese vaping brand Aspire Global, a failed IPO candidate. The joint bookrunners are Tiger Brokers, TFI Securities, and SPDB International.

Recent Posts

Ten Microcap Companies Charged with Reg A Violations

Ten Microcap Companies Charged with Reg A Violations

May 22, 2023
Microcap IPO Surge Continues Amidst Silicon Valley Din

Microcap IPO Flow Slows to a Trickle

May 22, 2023
Bi-Monthly Report on SEC Oversight of Penny Stock Violations

Pyramids and a Ponzi, Bank Fraud, Mask Fraud & General Theft

May 22, 2023
DealFlow Events logo

PO Box 122
Syosset, NY 11791
(516) 876-8006
team@dealflowevents.com

Subscribe to our free newsletter

Stay informed on the latest weekly Microcap news.

SIGN UP

© DealFlow Financial Products, Inc. (d/b/a DealFlow Events). All rights reserved. DealFlow Events™ and The Microcap Conference™ and The Microcap Newsletter™ are trademarks of DealFlow Financial Products, Inc.

  • Deal Tables
  • News
  • Events
    • The Microcap Conference
    • The SPAC Conference
    • The Reg A Conference
    • The Venture Debt Conference
    • The DTC Healthcare Conference
    • The Healthcare Services
      Investment Conference
  • Free Sign Up
  • Register for The Microcap Conference